Alpa Laboratories Ltd
Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals[1]
- Market Cap ₹ 233 Cr.
- Current Price ₹ 111
- High / Low ₹ 145 / 69.9
- Stock P/E 11.2
- Book Value ₹ 83.0
- Dividend Yield 0.00 %
- ROCE 13.7 %
- ROE 11.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 45.1% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 7.12% over past five years.
- Company has a low return on equity of 9.02% over last 3 years.
- Earnings include an other income of Rs.19.6 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
56 | 56 | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 97 | |
53 | 51 | 54 | 47 | 56 | 57 | 76 | 79 | 90 | 101 | 85 | 100 | 88 | |
Operating Profit | 3 | 6 | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 10 |
OPM % | 5% | 10% | 6% | 13% | 11% | 7% | 2% | 7% | 8% | 10% | 9% | 8% | 10% |
0 | 1 | 2 | 6 | 4 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 20 | |
Interest | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 5 | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 |
Profit before tax | -3 | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 21 | 27 |
Tax % | 36% | 4% | -48% | 27% | 34% | 27% | 36% | 20% | 33% | 28% | 21% | 19% | |
-4 | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 17 | 21 | |
EPS in Rs | -2.08 | -2.45 | -0.67 | 3.68 | 2.85 | 2.27 | 1.40 | 1.94 | 3.45 | 6.72 | 6.00 | 7.98 | 9.90 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 7% |
3 Years: | 4% |
TTM: | -15% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 45% |
3 Years: | 49% |
TTM: | 12% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 48% |
3 Years: | 23% |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 8% |
3 Years: | 9% |
Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Reserves | 72 | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 124 | 141 | 154 |
17 | 23 | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 3 | 5 | 3 | |
14 | 15 | 13 | 27 | 20 | 17 | 21 | 21 | 33 | 28 | 30 | 25 | 32 | |
Total Liabilities | 125 | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 210 |
80 | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 11 | 11 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 | 109 | 128 |
45 | 54 | 113 | 118 | 100 | 79 | 64 | 56 | 80 | 70 | 81 | 72 | 71 | |
Total Assets | 125 | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 210 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 8 | -2 | -25 | -8 | -7 | -1 | 18 | -1 | 2 | 10 | 4 | |
-4 | -2 | 37 | -7 | 1 | -16 | -15 | -11 | 6 | -16 | 1 | -12 | |
2 | 4 | 7 | -6 | -2 | 4 | -5 | -1 | -0 | 5 | -3 | 2 | |
Net Cash Flow | 0 | 10 | 42 | -37 | -9 | -19 | -20 | 5 | 4 | -8 | 8 | -6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 127 | 130 | 156 | 234 | 169 | 151 | 141 | 105 | 133 | 124 | 186 | 138 |
Inventory Days | 132 | 148 | 76 | 196 | 131 | 140 | 105 | 90 | 102 | 81 | 84 | 73 |
Days Payable | 85 | 121 | 91 | 244 | 140 | 130 | 99 | 98 | 152 | 78 | 100 | 63 |
Cash Conversion Cycle | 174 | 157 | 141 | 187 | 160 | 161 | 148 | 97 | 83 | 127 | 170 | 149 |
Working Capital Days | 187 | 169 | 178 | 390 | 256 | 234 | 194 | 121 | 137 | 136 | 157 | 150 |
ROCE % | -1% | -3% | 0% | 10% | 11% | 7% | 4% | 7% | 7% | 9% | 11% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
14 Nov - Resignation of Company Secretary effective December 10, 2024.
- Financial Results For The Quarter And Half Year Ended 30Th September,2024 14 Nov
-
Board Meeting Outcome for Financial Results For The Quarter And Half Year Ended 30Th September,2024
14 Nov - Approval of un-audited financial results for Q2 2024.
-
Board Meeting Intimation for Quarter And Half Year Ended September,2024
6 Nov - Board meeting to consider Q2 financial results.
-
Intimation Of Website Maintenance
26 Oct - Temporary website maintenance from 26.10.2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Business Overview:[1]
ALL is a WHO-GMP and ISO 9001:2000 certified company. It manufactures a wide range of Pharmaceutical Finished Dosage Forms under its own brand and for other Indian and multinational companies. The product range includes a wide variety of ethical, generic, and over-the-counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use